Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.

@article{Tannenbaum2004LumiracoxibIE,
  title={Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.},
  author={Hyman Tannenbaum and Francis Berenbaum and J-Y. Reginster and Jim Zacher and Joan Robinson and Gyula Po{\'o}r and Henning Bliddal and Daniel Uebelhart and Sandra Adami and Federico Navarro and Alvin Lee and A Moore and Alessandro Gimona},
  journal={Annals of the rheumatic diseases},
  year={2004},
  volume={63 11},
  pages={1419-26}
}
OBJECTIVES To compare the efficacy and safety of lumiracoxib with placebo and celecoxib for osteoarthritis OA in a 13 week, multicentre, randomised, double blind study. METHODS After a 37 day washout period for nonsteroidal antiinflammatory drugs, 1702 patients with knee OA were randomised to lumiracoxib 200 or 400 mg once daily od, celecoxib 200 mg od, or placebo 2221. A visual analogue scale VAS pain intensity > or =40 mm was required. Primary efficacy variables were OA pain intensity VAS… CONTINUE READING
27 Extracted Citations
40 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 27 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 40 references

Gastroduodenal safety and tolerability of lumiracoxib in patients with rheumatoid arthritis

  • AJ Kivitz, S Nayiager, T Schimansky, A Gimona, HJ Thurston, CJ. Hawkey
  • Ann Rheum Dis 2003;62(Suppl
  • 2003
1 Excerpt

Lumiracoxib demonstrates dose-proportional and time-independent pharmacokinetics in patients with osteoarthritis of the knee

  • G Scott, J Branson, S Milosavljev, C Rordorf, B Haraoui, J-P Ouellet
  • Ann Rheum Dis 2003;62(Suppl
  • 2003
1 Excerpt

Lumiracoxib demonstrates high absolute bioavailability in healthy subjects. Poster P-199 presented at 6 European Association of Clinical Pharmacology and Therapeutics (EACPT

  • S Hartmann, G Scott, C Rordorf, J Campestrini, J Branson, U. Keller
  • 2003
1 Excerpt

Lumiracoxib demonstrates preferential distribution to inflamed tissue in the rat following a single oral dose: an effect not seen with other cyclooxygenase-2 inhibitors

  • ML Weaver, DJ Flood, EF Kimble, RA. Fujimoto
  • Ann Rheum Dis 2003;62(Suppl
  • 2003

Lumiracoxib is effective and well tolerated in patients with osteoarthritis of the hand: results from a randomized, placebo-controlled trial

  • J Grifka, J Zacher, J Brown, B Seriolo, A Lee, A Moore
  • Ann Rheum Dis 2003;62(Suppl
  • 2003

Similar Papers

Loading similar papers…